The first and only approved achondroplasia therapy to provide continuous systemic exposure to CNP over the weekly dosing ...

Achondroplasia, also known as short-limb dwarfism, is associated with neurological symptoms and complications due to narrowing of the skeletal structures surrounding the spinal cord.

Researchers from The University of Osaka have developed a mouse model for achondroplasia. The model identified the importance ...

Yuviwel is administered once weekly and designed to provide continuous exposure of active c-type natriuretic peptide to receptors on tissues throughout the body to counteract the ...

By Sahil Pandey and Puyaan Singh Feb 27 (Reuters) - The U.S. Food and Drug Administration on Friday approved Ascendis Pharma's once-weekly therapy for children with a rare genetic disorder that causes ...

An investigational oral medication conferred an increase in annualized height velocity at 1 year among children and ...

Shares in BridgeBio were ticking up today after it revealed data from its phase 3 trial of infigratinib in achondroplasia, ...

Achondroplasia is a bone growth disorder caused by a mutation in the FGFR3 gene, resulting in disproportionate short stature and significant health complications. Infigratinib is an investigational ...

Peter Dinklage is most famous for his role as Tyrion Lannister from the series Game of Thrones. However, the popular actor ...

Shrewsbury's Steph Birch and her family, who have height-limiting achondroplasia, feel humiliated.

The rare disease drugmaker is facing potential competitors for achondroplasia drug Voxzogo. Is a big M&A deal with two approved assets enough to maintain investor interest?

A year of daily subcutaneous vosoritide was associated with a 0.6-inch (1.5-cm) greater increase in height than placebo in children with achondroplasia, the most common form of human dwarfism. There ...